A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: Quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting

British Journal of Dermatology

Volumn 158, Issue 2, 2008, Pages 375-381

  De Korte, J ^a   Van Der Valk, P G M ^b   Sprangers, M A G ^a   Damstra, R J ^c   Kunkeler, A C M ^d   Lijnen, R L P ^e   Oranje, A P ^f   De Rie, M A ^a   De Waard Van Der Spek, F B ^f   Hol, C W ^g   Van De Kerkhof, P C M ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NIJ SMELLINGHE HOSPITAL   (Netherlands)

^d Reinier de Graaf Groep: Diaconessenhuis Voorburg ^*  (Netherlands)

^e LAURENTIUS HOSPITAL   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g LEO Pharma   (Netherlands)

Author keywords

Calcipotriol; Day care; Dithranol; Psoriasis; Quality of life; Randomized controlled trial

Indexed keywords

CALCIPOTRIOL; DITHRANOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPING BEHAVIOR; DAY CARE; DOSAGE SCHEDULE COMPARISON; FEMALE; HEALTH VISITOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SOCIAL PSYCHOLOGY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANTHRALIN; CALCITRIOL; DAY CARE; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; OINTMENTS; PROSPECTIVE STUDIES; PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 38349098952     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08337.x     Document Type: Article

References (28)

1. 3 (MC 903) in a double-blind study. Br J Dermatol 1988 119 : 223 30.
2. Cunliffe WJ, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992 26 : 736 43.
3. Kragballe K, Gjertsen BT, de Hoop D et al. Double blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991 337 : 193 6.
4. Bruce S, Epinette WW, Funicella T et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994 31 : 755 9.
5. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002 146 : 351 64.
6. Gerritsen MJP. Dithranol. In : Textbook of Psoriasis (van de Kerkhof PCM, ed. 2nd edn. Oxford : Blackwell Science, 2003 170 90.
7. Swinkels OQJ, Prins M, Veenhuis RT et al. Effectiveness and side effects of UVB-phototherapy, dithranol inpatient therapy and a care instruction program of short contact dithranol in moderate to severe psoriasis. Eur J Dermatol 2004 14 : 159 65.
8. van de Kerkhof PCM, van der Valk PGM, Swinkels OQJ et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol 2006 155 : 800 7.
9. Faust HB, Mirowski GW, Chuang T et al. Outcomes research: an overview. J Am Acad Dermatol 1997 36 : 999 1006.
10. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997 136 : 305 14.
11. McKenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol 1996 34 : 534 8.
12. Rajagopalan R, Sheretz EF, Anderson R, eds. Care Management of Skin Diseases: Life Quality and Economic Impact. New York, NY : Marcel Dekker, 1998.
13. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997 133 : 1433 40.
14. de Korte J, Mombers FMC, Sprangers MAG, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002 138 : 1221 7.
15. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: a User's Manual. Boston, MA : The Health Institute, New England Medical Center, 1994.
16. Ware JE, Snow KK, Kosinski M et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA : The Health Institute, New England Medical Center, 1993.
17. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trail of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004 150 : 317 26.
18. Lundberg L, Johannesson M, Silverdahl M et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol (Stockh) 2000 80 : 430 4.
19. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 7.
20. Wahl A, Moum T, Hanestad BR, Wiklund I. The relationship between demographic and clinical variables, and quality of life aspects in patients with psoriasis. Qual Life Res 1999 8 : 319 26.
21. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ : Lawrence Erlbaum Associates, 1998.
22. de Korte J, Sprangers MAG, Mombers FMC, Bos JD. Quality of life in patients with psoriasis, a systematic literature review. J Investig Dermatol Symp Proc 2004 9 : 140 7.
23. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CEM. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997 137 : 755 60.
24. de Korte J, van Onselen J, Kownacki S et al. Quality of care in patients with psoriasis: an initial clinical study of an international disease-management programme. J Eur Acad Dermatol Venereol 2005 19 : 35 41.
25. Nichol MB, Margolies JE, Lippa E et al. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996 10 : 644 53.
26. Swinkels OQJ. Innovations in Dithranol Treatment of Psoriasis. Thesis, University Medical Center Nijmegen, 2002.
27. Ramsay CA, Berth-Jones J, Brundin G et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994 189 : 260 4.
28. Prins M. Dithranol in Psoriasis Day-care, the Short-contact Principle. Thesis, University Medical Center Nijmegen, 2002.